Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03657628 · ClinicalTrials.gov registry record · NA

Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue

A NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT03657628 is a NA study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 60 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03657628, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating the effect of exercise on markers in breast tissue and blood of premenopausal women who have been found to have dense breast tissue on mammogram.

Conditions Studied

Interventions

  • OTHER Exercise Intervention

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-09-17
Est. Completion 2026-12-31
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT03657628

The ClinicalTrials.gov registry entry for NCT03657628 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exercise Intervention is the first listed.

NCT03657628 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03657628 about?

NCT03657628 is a clinical study titled "Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue". This research study is evaluating the effect of exercise on markers in breast tissue and blood of premenopausal women who have been found to have dense breast tissue on mammogram.

What is the current status of trial NCT03657628?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2018-09-17. Estimated completion is 2026-12-31.

What conditions does trial NCT03657628 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03657628?

The interventions under investigation include: Exercise Intervention (OTHER).

Who is sponsoring clinical trial NCT03657628?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03657628 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.